Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Tick saliva protein Evasin-3 modulates chemotaxis by disrupting CXCL8 interactions with glycosaminoglycans and CXCR2.

Denisov SS, Ippel JH, Heinzmann ACA, Koenen RR, Ortega-Gomez A, Soehnlein O, Hackeng TM, Dijkgraaf I.

J Biol Chem. 2019 Aug 16;294(33):12370-12379. doi: 10.1074/jbc.RA119.008902. Epub 2019 Jun 24.

2.

Synthesis of Constrained Tetracyclic Peptides by Consecutive CEPS, CLIPS, and Oxime Ligation.

Streefkerk DE, Schmidt M, Ippel JH, Hackeng TM, Nuijens T, Timmerman P, van Maarseveen JH.

Org Lett. 2019 Apr 5;21(7):2095-2100. doi: 10.1021/acs.orglett.9b00378. Epub 2019 Mar 26.

3.

SecScan: a general approach for mapping disulfide bonds in synthetic and recombinant peptides and proteins.

Denisov SS, Ippel JH, Mans BJ, Dijkgraaf I, Hackeng TM.

Chem Commun (Camb). 2019 Jan 29;55(10):1374-1377. doi: 10.1039/c8cc08777f.

PMID:
30520894
4.

Blocking CCL5-CXCL4 heteromerization preserves heart function after myocardial infarction by attenuating leukocyte recruitment and NETosis.

Vajen T, Koenen RR, Werner I, Staudt M, Projahn D, Curaj A, Sönmez TT, Simsekyilmaz S, Schumacher D, Möllmann J, Hackeng TM, Hundelshausen PV, Weber C, Liehn EA.

Sci Rep. 2018 Jul 13;8(1):10647. doi: 10.1038/s41598-018-29026-0.

5.

A One-Pot "Triple-C" Multicyclization Methodology for the Synthesis of Highly Constrained Isomerically Pure Tetracyclic Peptides.

Richelle GJJ, Schmidt M, Ippel H, Hackeng TM, van Maarseveen JH, Nuijens T, Timmerman P.

Chembiochem. 2018 Sep 17;19(18):1934-1938. doi: 10.1002/cbic.201800346. Epub 2018 Aug 2.

PMID:
29944773
6.

Factor V Has Anticoagulant Activity in Plasma in the Presence of TFPIα: Difference between FV1 and FV2.

van Doorn P, Rosing J, Duckers C, Hackeng TM, Simioni P, Castoldi E.

Thromb Haemost. 2018 Jul;118(7):1194-1202. doi: 10.1055/s-0038-1656549. Epub 2018 Jun 4.

PMID:
29864781
7.

Suppressive Role of Tissue Factor Pathway Inhibitor-α in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength.

Thomassen S, Mastenbroek TG, Swieringa F, Winckers K, Feijge MAH, Schrijver R, Cosemans JMEM, Maroney SA, Mast AE, Hackeng TM, Heemskerk JWM.

Thromb Haemost. 2018 Mar;118(3):502-513. doi: 10.1055/s-0038-1627453. Epub 2018 Feb 16.

8.

Use of Cyclic Backbone NGR-Based SPECT to Increase Efficacy of Postmyocardial Infarction Angiogenesis Imaging.

Hendrikx G, Hackeng TM, van Gorp R, Bauwens M, Schurgers LJ, Mottaghy FM, Post MJ, Dijkgraaf I.

Contrast Media Mol Imaging. 2017 Oct 24;2017:8638549. doi: 10.1155/2017/8638549. eCollection 2017.

9.

Coagulation factor and protease pathways in thrombosis and cardiovascular disease.

Ten Cate H, Hackeng TM, García de Frutos P.

Thromb Haemost. 2017 Jun 28;117(7):1265-1271. doi: 10.1160/TH17-02-0079. Epub 2017 Jun 8. Review.

PMID:
28594052
10.

Detection of Localized Hepatocellular Amino Acid Kinetics by using Mass Spectrometry Imaging of Stable Isotopes.

Arts M, Soons Z, Ellis SR, Pierzchalski KA, Balluff B, Eijkel GB, Dubois LJ, Lieuwes NG, Agten SM, Hackeng TM, van Loon LJC, Heeren RMA, Olde Damink SWM.

Angew Chem Int Ed Engl. 2017 Jun 12;56(25):7146-7150. doi: 10.1002/anie.201702669. Epub 2017 May 11.

11.

Vascular CXCR4 Limits Atherosclerosis by Maintaining Arterial Integrity: Evidence From Mouse and Human Studies.

Döring Y, Noels H, van der Vorst EPC, Neideck C, Egea V, Drechsler M, Mandl M, Pawig L, Jansen Y, Schröder K, Bidzhekov K, Megens RTA, Theelen W, Klinkhammer BM, Boor P, Schurgers L, van Gorp R, Ries C, Kusters PJH, van der Wal A, Hackeng TM, Gäbel G, Brandes RP, Soehnlein O, Lutgens E, Vestweber D, Teupser D, Holdt LM, Rader DJ, Saleheen D, Weber C.

Circulation. 2017 Jul 25;136(4):388-403. doi: 10.1161/CIRCULATIONAHA.117.027646. Epub 2017 Apr 27.

12.

Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation.

von Hundelshausen P, Agten SM, Eckardt V, Blanchet X, Schmitt MM, Ippel H, Neideck C, Bidzhekov K, Leberzammer J, Wichapong K, Faussner A, Drechsler M, Grommes J, van Geffen JP, Li H, Ortega-Gomez A, Megens RT, Naumann R, Dijkgraaf I, Nicolaes GA, Döring Y, Soehnlein O, Lutgens E, Heemskerk JW, Koenen RR, Mayo KH, Hackeng TM, Weber C.

Sci Transl Med. 2017 Apr 5;9(384). pii: eaah6650. doi: 10.1126/scitranslmed.aah6650.

PMID:
28381538
13.

Deletion of junctional adhesion molecule A from platelets increases early-stage neointima formation after wire injury in hyperlipidemic mice.

Zhao Z, Vajen T, Karshovska E, Dickhout A, Schmitt MM, Megens RTA, von Hundelshausen P, Koeppel TA, Hackeng TM, Weber C, Koenen RR.

J Cell Mol Med. 2017 Aug;21(8):1523-1531. doi: 10.1111/jcmm.13083. Epub 2017 Feb 17.

14.

New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasma.

Alshaikh NA, Rosing J, Thomassen MCLGD, Castoldi E, Simioni P, Hackeng TM.

J Thromb Haemost. 2017 May;15(5):950-960. doi: 10.1111/jth.13657. Epub 2017 Mar 20.

15.

Platelet full length TFPI-α in healthy volunteers is not affected by sex or hormonal use.

Winckers K, Thomassen S, Ten Cate H, Hackeng TM.

PLoS One. 2017 Feb 3;12(2):e0168273. doi: 10.1371/journal.pone.0168273. eCollection 2017.

16.

Prothrombin Loading of Vascular Smooth Muscle Cell-Derived Exosomes Regulates Coagulation and Calcification.

Kapustin AN, Schoppet M, Schurgers LJ, Reynolds JL, McNair R, Heiss A, Jahnen-Dechent W, Hackeng TM, Schlieper G, Harrison P, Shanahan CM.

Arterioscler Thromb Vasc Biol. 2017 Mar;37(3):e22-e32. doi: 10.1161/ATVBAHA.116.308886. Epub 2017 Jan 19.

PMID:
28104608
17.

Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity.

Wentink MQ, Hackeng TM, Tabruyn SP, Puijk WC, Schwamborn K, Altschuh D, Meloen RH, Schuurman T, Griffioen AW, Timmerman P.

Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12532-12537. Epub 2016 Oct 17.

18.

The C-terminus of tissue factor pathway inhibitor-α inhibits factor V activation by protecting the Arg1545 cleavage site.

van Doorn P, Rosing J, Wielders SJ, Hackeng TM, Castoldi E.

J Thromb Haemost. 2017 Jan;15(1):140-149. doi: 10.1111/jth.13559. Epub 2016 Dec 3. Erratum in: J Thromb Haemost. 2019 Jul;17(7):1195.

19.

Probing Functional Heteromeric Chemokine Protein-Protein Interactions through Conformation-Assisted Oxime Ligation.

Agten SM, Koenen RR, Ippel H, Eckardt V, von Hundelshausen P, Mayo KH, Weber C, Hackeng TM.

Angew Chem Int Ed Engl. 2016 Nov 21;55(48):14963-14966. doi: 10.1002/anie.201607036. Epub 2016 Oct 27.

20.

Oxime conjugation in protein chemistry: from carbonyl incorporation to nucleophilic catalysis.

Agten SM, Dawson PE, Hackeng TM.

J Pept Sci. 2016 May;22(5):271-9. doi: 10.1002/psc.2874. Epub 2016 Mar 23. Review.

PMID:
27006095
21.

Structure-Based Design of Peptidic Inhibitors of the Interaction between CC Chemokine Ligand 5 (CCL5) and Human Neutrophil Peptides 1 (HNP1).

Wichapong K, Alard JE, Ortega-Gomez A, Weber C, Hackeng TM, Soehnlein O, Nicolaes GA.

J Med Chem. 2016 May 12;59(9):4289-301. doi: 10.1021/acs.jmedchem.5b01952. Epub 2016 Feb 23.

PMID:
26871718
22.

Coated platelets function in platelet-dependent fibrin formation via integrin αIIbβ3 and transglutaminase factor XIII.

Mattheij NJ, Swieringa F, Mastenbroek TG, Berny-Lang MA, May F, Baaten CC, van der Meijden PE, Henskens YM, Beckers EA, Suylen DP, Nolte MW, Hackeng TM, McCarty OJ, Heemskerk JW, Cosemans JM.

Haematologica. 2016 Apr;101(4):427-36. doi: 10.3324/haematol.2015.131441. Epub 2015 Dec 31.

23.

Recruitment of classical monocytes can be inhibited by disturbing heteromers of neutrophil HNP1 and platelet CCL5.

Alard JE, Ortega-Gomez A, Wichapong K, Bongiovanni D, Horckmans M, Megens RT, Leoni G, Ferraro B, Rossaint J, Paulin N, Ng J, Ippel H, Suylen D, Hinkel R, Blanchet X, Gaillard F, D'Amico M, von Hundelshausen P, Zarbock A, Scheiermann C, Hackeng TM, Steffens S, Kupatt C, Nicolaes GA, Weber C, Soehnlein O.

Sci Transl Med. 2015 Dec 9;7(317):317ra196. doi: 10.1126/scitranslmed.aad5330.

PMID:
26659570
24.

Oxime Catalysis by Freezing.

Agten SM, Suylen DP, Hackeng TM.

Bioconjug Chem. 2016 Jan 20;27(1):42-6. doi: 10.1021/acs.bioconjchem.5b00611. Epub 2015 Dec 15.

PMID:
26649643
25.

Role of exosite binding modulators in the inhibition of Fxa by TFPI.

Peraramelli S, Thomassen S, Heinzmann A, Hackeng TM, Hartmann R, Scheiflinger F, Dockal M, Rosing J.

Thromb Haemost. 2016 Mar;115(3):580-90. doi: 10.1160/TH15-04-0354. Epub 2015 Nov 26.

PMID:
26607136
26.

Molecular imaging of angiogenesis after myocardial infarction by (111)In-DTPA-cNGR and (99m)Tc-sestamibi dual-isotope myocardial SPECT.

Hendrikx G, De Saint-Hubert M, Dijkgraaf I, Bauwens M, Douma K, Wierts R, Pooters I, Van den Akker NM, Hackeng TM, Post MJ, Mottaghy FM.

EJNMMI Res. 2015 Jan 28;5:2. doi: 10.1186/s13550-015-0081-7. eCollection 2015.

27.

Discovery of small molecule CD40-TRAF6 inhibitors.

Zarzycka B, Seijkens T, Nabuurs SB, Ritschel T, Grommes J, Soehnlein O, Schrijver R, van Tiel CM, Hackeng TM, Weber C, Giehler F, Kieser A, Lutgens E, Vriend G, Nicolaes GA.

J Chem Inf Model. 2015 Feb 23;55(2):294-307. doi: 10.1021/ci500631e. Epub 2015 Jan 27.

PMID:
25622654
28.

Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation.

Dargaud Y, Scoazec JY, Wielders SJ, Trzeciak C, Hackeng TM, Négrier C, Hemker HC, Lindhout T, Castoldi E.

Blood. 2015 Feb 26;125(9):1497-501. doi: 10.1182/blood-2014-10-604553. Epub 2015 Jan 6.

29.

Hyperreactivity of junctional adhesion molecule A-deficient platelets accelerates atherosclerosis in hyperlipidemic mice.

Karshovska E, Zhao Z, Blanchet X, Schmitt MM, Bidzhekov K, Soehnlein O, von Hundelshausen P, Mattheij NJ, Cosemans JM, Megens RT, Koeppel TA, Schober A, Hackeng TM, Weber C, Koenen RR.

Circ Res. 2015 Feb 13;116(4):587-99. doi: 10.1161/CIRCRESAHA.116.304035. Epub 2014 Dec 3.

PMID:
25472975
30.

Tissue factor-independent inhibition of thrombin generation by tissue factor pathway inhibitor-α.

Thomassen MC, Heinzmann AC, Herfs L, Hartmann R, Dockal M, Scheiflinger F, Hackeng TM, Rosing J.

J Thromb Haemost. 2015 Jan;13(1):92-100. doi: 10.1111/jth.12766. Epub 2014 Nov 29.

31.

Inhibition of tissue factor:factor VIIa-catalyzed factor IX and factor X activation by TFPI and TFPI constructs.

Peraramelli S, Thomassen S, Heinzmann A, Rosing J, Hackeng TM, Hartmann R, Scheiflinger F, Dockal M.

J Thromb Haemost. 2014 Nov;12(11):1826-37. doi: 10.1111/jth.12713. Epub 2014 Oct 12.

32.

Imaging evidence for endothelin ETA/ETB receptor heterodimers in isolated rat mesenteric resistance arteries.

Kapsokalyvas D, Schiffers PM, Maij N, Suylen DP, Hackeng TM, van Zandvoort MA, De Mey JG.

Life Sci. 2014 Aug 28;111(1-2):36-41. doi: 10.1016/j.lfs.2014.07.007. Epub 2014 Jul 24.

PMID:
25066928
33.

Atherogenic mononuclear cell recruitment is facilitated by oxidized lipoprotein-induced endothelial junctional adhesion molecule-A redistribution.

Schmitt MM, Fraemohs L, Hackeng TM, Weber C, Koenen RR.

Atherosclerosis. 2014 Jun;234(2):254-64. doi: 10.1016/j.atherosclerosis.2014.03.014. Epub 2014 Mar 25.

PMID:
24704627
34.

Controlled intramyocardial release of engineered chemokines by biodegradable hydrogels as a treatment approach of myocardial infarction.

Projahn D, Simsekyilmaz S, Singh S, Kanzler I, Kramp BK, Langer M, Burlacu A, Bernhagen J, Klee D, Zernecke A, Hackeng TM, Groll J, Weber C, Liehn EA, Koenen RR.

J Cell Mol Med. 2014 May;18(5):790-800. doi: 10.1111/jcmm.12225. Epub 2014 Feb 6.

35.

(1)H, (13)C, and (15)N backbone and side-chain chemical shift assignments for the 36 proline-containing, full length 29 kDa human chimera-type galectin-3.

Ippel H, Miller MC, Berbís MA, Suylen D, André S, Hackeng TM, Cañada FJ, Weber C, Gabius HJ, Jiménez-Barbero J, Mayo KH.

Biomol NMR Assign. 2015 Apr;9(1):59-63. doi: 10.1007/s12104-014-9545-3. Epub 2014 Feb 7.

36.

Chemoselective oxime reactions in proteins and peptides by using an optimized oxime strategy: the demise of levulinic acid.

Agten SM, Suylen D, Ippel H, Kokozidou M, Tans G, van de Vijver P, Koenen RR, Hackeng TM.

Chembiochem. 2013 Dec 16;14(18):2431-4. doi: 10.1002/cbic.201300598. Epub 2013 Oct 22. No abstract available.

PMID:
24151209
37.

Antisense-based RNA therapy of factor V deficiency: in vitro and ex vivo rescue of a F5 deep-intronic splicing mutation.

Nuzzo F, Radu C, Baralle M, Spiezia L, Hackeng TM, Simioni P, Castoldi E.

Blood. 2013 Nov 28;122(23):3825-31. doi: 10.1182/blood-2013-04-499657. Epub 2013 Oct 1.

38.

Endothelial junctional adhesion molecule-a guides monocytes into flow-dependent predilection sites of atherosclerosis.

Schmitt MM, Megens RT, Zernecke A, Bidzhekov K, van den Akker NM, Rademakers T, van Zandvoort MA, Hackeng TM, Koenen RR, Weber C.

Circulation. 2014 Jan 7;129(1):66-76. doi: 10.1161/CIRCULATIONAHA.113.004149. Epub 2013 Sep 24.

PMID:
24065611
39.

Plasma protein S residues 37-50 mediate its binding to factor Va and inhibition of blood coagulation.

Heeb MJ, Mesters RM, Fernández JA, Hackeng TM, Nakasone RK, Griffin JH.

Thromb Haemost. 2013 Aug;110(2):275-82. doi: 10.1160/TH12-12-0953. Epub 2013 May 23.

40.

Synthesis and application of cNGR-containing imaging agents for detection of angiogenesis.

Dijkgraaf I, Van de Vijver P, Dirksen A, Hackeng TM.

Bioorg Med Chem. 2013 Jun 15;21(12):3555-64. doi: 10.1016/j.bmc.2013.04.002. Epub 2013 Apr 13. Review.

PMID:
23643902
41.

The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis.

Winckers K, ten Cate H, Hackeng TM.

Blood Rev. 2013 May;27(3):119-32. doi: 10.1016/j.blre.2013.03.001. Epub 2013 Apr 28. Review.

PMID:
23631910
42.

Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner.

Borissoff JI, Otten JJ, Heeneman S, Leenders P, van Oerle R, Soehnlein O, Loubele ST, Hamulyák K, Hackeng TM, Daemen MJ, Degen JL, Weiler H, Esmon CT, van Ryn J, Biessen EA, Spronk HM, ten Cate H.

PLoS One. 2013;8(2):e55784. doi: 10.1371/journal.pone.0055784. Epub 2013 Feb 7.

43.

Direct inhibition of factor VIIa by TFPI and TFPI constructs.

Peraramelli S, Thomassen S, Heinzmann A, Rosing J, Hackeng TM, Hartmann R, Scheiflinger F, Dockal M.

J Thromb Haemost. 2013 Apr;11(4):704-14. doi: 10.1111/jth.12152.

44.

Plaque-associated vasa vasorum in aged apolipoprotein E-deficient mice exhibit proatherogenic functional features in vivo.

Rademakers T, Douma K, Hackeng TM, Post MJ, Sluimer JC, Daemen MJ, Biessen EA, Heeneman S, van Zandvoort MA.

Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):249-56. doi: 10.1161/ATVBAHA.112.300087. Epub 2012 Dec 13.

PMID:
23241413
45.

Clinical perspectives of hybrid proton-fluorine magnetic resonance imaging and spectroscopy.

Wolters M, Mohades SG, Hackeng TM, Post MJ, Kooi ME, Backes WH.

Invest Radiol. 2013 May;48(5):341-50. doi: 10.1097/RLI.0b013e318277528c. Review.

PMID:
23211551
46.

Incorporation of disulfide containing protein modules into multivalent antigenic conjugates: generation of antibodies against the thrombin-sensitive region of murine protein S.

Van de Vijver P, Schmitt M, Suylen D, Scheer L, Thomassen MC, Schurgers LJ, Griffin JH, Koenen RR, Hackeng TM.

J Am Chem Soc. 2012 Nov 28;134(47):19318-21. doi: 10.1021/ja306993t. Epub 2012 Nov 13.

PMID:
23066897
47.

Impaired tissue factor pathway inhibitor function is associated with recurrent venous thromboembolism in patients with first unprovoked deep venous thrombosis.

Winckers K, Ten Cate-Hoek AJ, Beekers KC, Erkens P, Hamulyák K, Ten Cate H, Hackeng TM.

J Thromb Haemost. 2012 Oct;10(10):2208-11. doi: 10.1111/j.1538-7836.2012.04884.x. No abstract available.

48.

Application of an omonasteine ligation strategy for the total chemical synthesis of the BRD7 bromodomain.

Van de Vijver P, Scheer L, van Beijnum J, Griffioen A, Hackeng TM.

Chem Commun (Camb). 2012 Sep 28;48(75):9403-5. doi: 10.1039/c2cc34956f. Epub 2012 Aug 13.

PMID:
22889936
49.

The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa.

Peraramelli S, Suylen DP, Rosing J, Hackeng TM.

Thromb Haemost. 2012 Aug;108(2):266-76. doi: 10.1160/TH11-12-0902. Epub 2012 May 25.

PMID:
22627666
50.

Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists.

Chatrou ML, Winckers K, Hackeng TM, Reutelingsperger CP, Schurgers LJ.

Blood Rev. 2012 Jul;26(4):155-66. doi: 10.1016/j.blre.2012.03.002. Epub 2012 Apr 18. Review.

PMID:
22520397

Supplemental Content

Loading ...
Support Center